Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in Benin city, Nigeria

Oman Medical Journal

Volumn 27, Issue 3, 2012, Pages 228-231

  Osazuwa, Favour ^a,b   Dirisu, John Osilume ^a,c   Okuonghae, Patrick Evbaguehita ^a   Ugbebor, Ose ^a  

^a UNIVERSITY OF BENIN   (Nigeria)

^b MOD/US DOD HIV/AIDS control programme   (Nigeria)

^c Lahor Research Laboratory   (Nigeria)

Author keywords

Art na ve aids patients; CD4 t cell counts; Cryptococcal antigen; Sero prevalence

Indexed keywords

FUNGUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLOW CYTOMETRY; HUMAN; LABORATORY DIAGNOSIS; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NIGERIA; PATHOGENESIS; SCREENING; SEROPREVALENCE; SEX DIFFERENCE;

EID: 84864473435     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2012.51     Document Type: Article

References (23)

1. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998 Aug;27(4):698-702.
2. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009 Jun;51(2):130-134.
3. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997 Jul;337(1):15-21.
4. Michaels SH, Clark R, Kissinger P. Incidence and spectrum of AIDSdefining illnesses among persons treated with antiretroviral drugs. Clin Infect Dis 1999 Aug;29(2):468-469.
5. Benson CA, Kaplan JE, Masor H, Alice P, Holmes KK. Treatment of opportunistic infections among HIV infected Adults and Adolescents. Recommendations and reports. Morbidity and Mortality weekly Report 2004;53:110-112.
6. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptocococcis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:103-107.
7. Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991 Jan-Feb;13(1):64-67.
8. Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 2000 Jul-Aug;1(1):1-6.
9. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005 Dec;51(5):e289-e297.
10. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989 Feb;3(2):77-78.
11. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007 Aug;12(8):929-935.
12. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010 Aug;51(4):448-455.
13. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009 Apr;48(7):856-862.
14. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 2010 Jun;60(6):474-477.
15. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, Dousset JP, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007 Aug;45(5):555-559.
16. Aluyi HA, Otajevwo FD, Iweriebor O. Incidence of pulmonary mycoses in patients with acquired immunodeficiency diseases. Niger J Clin Pract 2010;13:78-83.
17. Lara-Peredo O, Cuevas LE, French N, Bailey JW, Smith DH. Cryptococcal infection in an HIV-positive Ugandan population. J Infect 2000 Sep;41(2):195.
18. Kisenge PR, Hawkins AT, Maro VP, McHele JP, Swai NS, Mueller A, et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007; 10; 7:39.
19. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect 2010 Jun;60(6):496-498.
20. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994 Dec;19(6):1029-1033.
21. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009 Sep;49(6):965-972.
22. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005 Nov;19(17):2050-2052.
23. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend Rep 2009; 58(RR-4):1-207. Quiz CE1-4.